Option Care Health Announces Financial Results for the First Quarter and Provides an Update on the Impact of COVID-19 Pandemic
Given the merger between
First Quarter 2020 Financial Highlights
- Net revenue of
$705.4 million , up 48.0% compared to$476.5 million in the first quarter of 2019 - Gross profit of
$158.0 million , or 22.4% of net revenue, up 60.9% compared to$98.2 million , or 20.6% of revenue, in the first quarter of 2019 - Net loss of
$19.9 million , or$0.11 per share, compared to net loss of$3.7 million , or$0.03 per share, in the first quarter of 2019 - Adjusted EBITDA of
$40.2 million , up 107.6% compared to$19.4 million in the first quarter of 2019 - Cash flow from operations of
$18.4 million , up 102.7% compared to$9.1 million in the first quarter of 2019 - Cash balances of
$77.2 million at the end of the first quarter and no outstanding borrowings on the Company’s$150.0 million revolver
Update on the Impact of the COVID-19 Pandemic
In March, at the onset of the pandemic, the Company established a centralized command center to focus on a coordinated and collaborative rapid response.
Based on the significant technology and infrastructure investments over the past five years, the Company quickly and efficiently enabled and supported a virtual and remote workforce for all key functions outside of our compounding pharmacies and has maintained overall business continuity. The Company has sought to aggressively procure necessary personal protective equipment and medical supplies to ensure the safety of our clinicians and adequate inventory levels. To date, the Company has maintained adequate levels of critical supplies.
With a network of more than 100 compounding facilities and approximately 2,900 clinicians,
Building upon the cash generation momentum from 2019, the Company has aggressively taken steps to optimize cash flow and preservation. To date, the Company has experienced no material deceleration in cash collections and collaboration with payers continues to be productive. Despite higher expenditures for certain critical medical supplies and drugs, cash flow generation continues to be robust. Based on the continued strong cash balances, the Company has not drawn on its revolver to date and monitors liquidity on a daily basis. Available borrowings under the facility, reduced by outstanding letters of credit, remains approximately
Looking forward, the pandemic is expected to impact the Company across a number of areas; however, such impacts cannot be accurately projected given the dynamic nature of the situation. Such affected areas may include, but are not limited to:
- Variability in acute therapy patient referrals from hospitals based on changes in hospital-based procedures and treatment patterns,
- Variability in chronic therapy patient referrals based on disruptions in the diagnosis of chronic conditions requiring infusion therapy,
- Inefficiencies in clinical labor expenses and higher labor costs from staffing disruptions and availability, potential overtime due to inefficient clinical staffing and utilization of contract labor, and
- Higher costs to procure, and potential unavailability of, critical personal protection equipment, pharmaceuticals and medical supplies given a constrained supply environment.
The leadership team of
Conference Call
The conference call can be accessed by dialing (866) 360-3136 for
About
Investor Contacts
Chief Financial Officer | Westwicke |
T: (312) 940-2538 | T: (413) 213-0500 |
mike.shapiro@optioncare.com | optioncarehealth@westwicke.com |
Forward-Looking Statements - Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key payers; and (v) the spread and impact of the COVID-19 pandemic. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(IN THOUSANDS) | |||||
(unaudited) | |||||
2020 | 2019 | ||||
ASSETS | |||||
CURRENT ASSETS: | |||||
Cash and cash equivalents | $ | 77,244 | $ | 67,056 | |
Accounts receivable, net | 337,197 | 324,416 | |||
Inventories | 139,128 | 115,876 | |||
Prepaid expenses and other current assets | 47,703 | 51,306 | |||
Total current assets | 601,272 | 558,654 | |||
NONCURRENT ASSETS: | |||||
Property and equipment, net | 125,786 | 133,198 | |||
Intangible assets, net | 377,196 | 385,910 | |||
1,427,883 | 1,425,542 | ||||
Other noncurrent assets | 80,394 | 86,243 | |||
Total noncurrent assets | 2,011,259 | 2,030,893 | |||
TOTAL ASSETS | $ | 2,612,531 | $ | 2,589,547 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
CURRENT LIABILITIES: | |||||
Accounts payable | $ | 265,703 | $ | 221,060 | |
Other current liabilities | 113,320 | 108,944 | |||
Total current liabilities | 379,023 | 330,004 | |||
NONCURRENT LIABILITIES: | |||||
Long-term debt, net of discount, deferred financing costs and current portion | 1,276,329 | 1,277,246 | |||
Other noncurrent liabilities | 86,686 | 75,470 | |||
Total noncurrent liabilities | 1,363,015 | 1,352,716 | |||
Total liabilities | 1,742,038 | 1,682,720 | |||
STOCKHOLDERS’ EQUITY | 870,493 | 906,827 | |||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 2,612,531 | $ | 2,589,547 | |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS | |||||||
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | |||||||
Three Months Ended |
|||||||
2020 | 2019 | ||||||
NET REVENUE | $ | 705,440 | $ | 476,492 | |||
COST OF REVENUE | 547,411 | 378,298 | |||||
GROSS PROFIT | 158,029 | 98,194 | |||||
OPERATING COSTS AND EXPENSES: | |||||||
Selling, general and administrative expenses | 129,280 | 82,787 | |||||
Depreciation and amortization expense | 20,101 | 9,969 | |||||
Total operating expenses | 149,381 | 92,756 | |||||
OPERATING INCOME | 8,648 | 5,438 | |||||
OTHER INCOME (EXPENSE): | |||||||
Interest expense, net | (28,087 | ) | (11,045 | ) | |||
Other, net | 570 | 473 | |||||
Total other expense | (27,517 | ) | (10,572 | ) | |||
LOSS BEFORE INCOME TAXES | (18,869 | ) | (5,134 | ) | |||
INCOME TAX EXPENSE (BENEFIT) | 1,041 | (1,422 | ) | ||||
NET LOSS | $ | (19,910 | ) | $ | (3,712 | ) | |
Net loss per share, basic and diluted | $ | (0.11 | ) | $ | (0.03 | ) | |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
(IN THOUSANDS) | |||||||
Three Months Ended |
|||||||
2020 | 2019 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net loss | $ | (19,910 | ) | $ | (3,712 | ) | |
Adjustments to reconcile net loss to net cash provided by operations: | |||||||
Depreciation and amortization expense | 21,844 | 10,749 | |||||
Other non-cash adjustments | 5,773 | 2,448 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | (12,781 | ) | 266 | ||||
Inventories | (23,252 | ) | (6,690 | ) | |||
Accounts payable | 42,302 | (3,395 | ) | ||||
Other | 4,427 | 9,414 | |||||
Net cash provided by operating activities | 18,403 | 9,080 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Acquisition of property and equipment | (5,353 | ) | (5,367 | ) | |||
Other investing cash flows | — | 636 | |||||
Net cash used in investing activities | (5,353 | ) | (4,731 | ) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Other financing cash flows | (2,862 | ) | (3,038 | ) | |||
Net cash used in financing activities | (2,862 | ) | (3,038 | ) | |||
NET INCREASE IN CASH AND CASH EQUIVALENTS | 10,188 | 1,311 | |||||
Cash and cash equivalents - beginning of the period | 67,056 | 36,391 | |||||
CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 77,244 | $ | 37,702 | |||
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES | |||||||
(IN THOUSANDS) | |||||||
(UNAUDITED) | |||||||
Three Months Ended |
|||||||
2020 | 2019 | ||||||
Consolidated net loss | $ | (19,910 | ) | $ | (3,712 | ) | |
Interest expense, net | 28,087 | 11,045 | |||||
Income tax expense (benefit) | 1,041 | (1,422 | ) | ||||
Depreciation and amortization expense | 21,844 | 10,749 | |||||
Consolidated EBITDA | 31,062 | 16,660 | |||||
EBITDA adjustments | |||||||
Accounting principle changes and non-cash charges | — | 1,535 | |||||
Stock-based incentive compensation | 757 | 584 | |||||
Restructuring, acquisition, integration and other | 8,360 | 577 | |||||
Consolidated adjusted EBITDA | $ | 40,179 | $ | 19,356 |
Source: Option Care Health, Inc.